Trials / Completed
CompletedNCT01861236
Effectiveness and Safety of Firmagon® in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma in Argentina
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 90 (actual)
- Sponsor
- Ferring Pharmaceuticals · Industry
- Sex
- Male
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
Prospective, observational study to collect and analyze data on patients with advanced hormone dependent prostate cancer treated with Firmagon® according to routine medical practice in Argentina
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Firmagon® (degarelix) | Monthly subcutaneous injections |
Timeline
- Start date
- 2013-03-01
- Primary completion
- 2018-09-03
- Completion
- 2018-09-03
- First posted
- 2013-05-23
- Last updated
- 2018-10-23
Locations
1 site across 1 country: Argentina
Source: ClinicalTrials.gov record NCT01861236. Inclusion in this directory is not an endorsement.